Research programme: 5T4 tumour antigen imaging - ImaginAb/Oxford BioMedicaAlternative Names: 5T4-targeted PET tracer - ImaginAb/Oxford BioMedica
Latest Information Update: 16 Jul 2016
At a glance
- Originator ImaginAb
- Developer ImaginAb Inc
- Class Antibodies; Antibody diagnostics; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer